Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.  Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Agriforce Growing Systems Ltd

Data Storage Corp

Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy This Week? 3 to Watch Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy This Week? 3 to Watch Right Now

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

HPN328, Harpoon's DLL3-targeting T cell engager, to be evaluated in combination with anti-PD-L1 antibody in patients with small cell lung cancer HPN328, Harpoon's DLL3-targeting T cell engager, to be evaluated in combination with anti-PD-L1 antibody in patients with small cell lung cancer

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index

Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, 2022. Dr. Sacks will serve as a consultant to Harpoon through the end of the year.

Harpoon Therapeutics Announces Leadership Change

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference. The discussion will take place on Thursday, April 14, 2022 at 2:30 p.m. ET (11:30 a.m. PT).

Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

Harpoon Therapeutics Inc (NASDAQ: HARP), in its Q4 FY21 earnings results, has given up on its onetime lead prospect HPN424.  "We are focusing our resources on portfolio programs that show promising activity, including HPN328 and HPN217, while we advance new candidates into the.

Harpoon Therapeutics Discontinues Its Once Lead Prostate Cancer Candidate

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -43.48% and 38.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q4 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a delta like ligand 3- (DLL3) targeting TriTAC®, for the treatment of small cell lung cancer (SCLC). A Phase 1/2 clinical trial is currently ongoing for HPN328 in the SCLC patient population.

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC®, for the treatment of patients with relapsed, refractory multiple myeloma (RRMM) who have received at least four lines of therapy. A Phase 1/2 clinical trial is currently ongoing for HPN217 in the RRMM patient population.

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. The discussion will take place on Wednesday, February 16, 2022 at 5 p.m. ET (2 p.m. PT).

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 274.4% in Harpoon Therapeutics, Inc. (HARP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 274% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline milestone update on its TriTAC development programs.

Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline update on its programs, including the interim data presented from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma (R/R MM) at the 63rd American Society for Hematology (ASH) Annual Meeting and Exposition. Harpoon has four product candidates in clinical trials that are based on its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.

Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms

Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with interim data from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma. Data were presented at the American Society for Hematology (ASH) Annual Meeting and Exposition.

Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet

Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review the clinical status and provide an update on its pipeline programs.

Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 1.92% and -29.75%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that management will participate in two upcoming virtual investor conferences:

Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held virtually and in person in Atlanta, Ga. from December 11-14, 2021.

Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition

Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harpoon Therapeutics, Inc. (HARP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Julie Eastland Appointed President and Chief Executive Officer

News for Harpoon Therapeutics Inc Stock (HARP)